Welcome to our dedicated page for Icecure Medical news (Ticker: ICCM), a resource for investors and traders seeking the latest updates and insights on Icecure Medical stock.
IceCure Medical Ltd. develops and markets liquid-nitrogen-based cryoablation systems for minimally invasive tumor destruction. Its flagship ProSense® system is used for benign and cancerous lesions, with company updates centered on breast, kidney, bone and lung cancer indications and on markets where the device is cleared or approved, including the United States, Europe and Asia.
News about ICCM commonly covers ProSense commercialization, FDA-related breast cancer developments, post-market study activity, clinical evidence such as the ICESECRET kidney cancer study, medical-conference presentations, financial and operating results, and governance changes. The company’s updates also address physician training, reimbursement context and shareholder matters tied to its ordinary shares.
IceCure Medical (NASDAQ: ICCM) announced the publication of a peer-reviewed article on the ICE3 Trial's interim results for cryoablation in low-risk, early-stage breast cancer. The study, published in the Annals of Surgical Oncology, found a low recurrence rate of just 2.06% (4 of 194 patients) at a mean follow-up of 34.83 months. CEO Eyal Shamir highlighted this milestone as a breakthrough in the adoption of their minimally invasive cryoablation technology. The procedure presents a promising alternative to surgery, with minimal risks and excellent cosmetic outcomes.
IceCure Medical (NASDAQ: ICCM) has signed an initial distribution agreement with Mutlu Medikim A.S. to exclusively sell its ProSense™ Cryoablation System in Turkey. The agreement aims to leverage Turkey's healthcare system, serving a population of over 80 million, to expand IceCure’s market presence. Mutlu Medikim A.S. plans to place an initial purchase order worth approximately $100,000, leading to expectations of a long-term agreement within a year. This partnership is part of IceCure's broader strategy to enhance distribution networks across multiple regions, including Europe and Asia.
IceCure Medical Ltd. (NASDAQ: ICCM) announced that its shares are now listed on the Nasdaq Capital Market, effective August 26, 2021. This milestone is expected to enhance the company's visibility and liquidity among U.S. and international investors. The Nasdaq listing follows a $15 million private placement in January 2021, aiming to expand IceCure's global reach in the minimally invasive cryoablation technology sector. The SEC has effectively approved the registration statement for shares related to this private placement.